Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acutus Medical, Inc.AFIB · Entity 83848 | Director | June 15, 2023 | June 15, 2023 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director · PRESIDENT & CEO | August 15, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acutus Medical, Inc.
Report date June 15, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| FORM 4SEC Table I · non-derivative | Direct | 24,347 |
Reported balance
After 2023-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-15 · Grant · Acquired 8,400 · Balance 24,347 F1: Common Stock F2: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the Shares of Common Stock ("Shares) subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director. |
| FORM 4SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2033-06-15 | Direct | 19,600 |
Reported balance
After 2023-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-15 · Grant · Acquired 19,600 · Balance 19,600 F3: Stock Options (Right to Buy) F4: Each annual stock option ("the Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, fi on such date the Reporting Person has remained in continuous service as director. F1: Common Stock |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock
F2: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the Shares of Common Stock ("Shares) subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director.
F3: Stock Options (Right to Buy)
F4: Each annual stock option ("the Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, fi on such date the Reporting Person has remained in continuous service as director.
TANDEM DIABETES CARE INC
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,260 |
Ending reported balance
After 2026-08-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-15 · Exercise / conversion · Acquired 5,982 · Balance 158,425 Row 2 · 2026-08-15 · Tax withholding · Disposed 3,044 · Balance 155,381 F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. Row 3 · 2026-08-15 · Exercise / conversion · Acquired 9,934 · Balance 165,315 Row 4 · 2026-08-15 · Tax withholding · Disposed 5,055 · Balance 160,260 F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 17,947 |
Reported balance
After 2026-08-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-15 · Exercise / conversion · Disposed 5,982 · Balance 17,947 F2: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4: One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 69,537 |
Reported balance
After 2026-08-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-15 · Exercise / conversion · Disposed 9,934 · Balance 69,537 F5: Awarded on May 30, 2025 pursuant to the 2023 Plan. F3: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
F2: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F3: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
F4: One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
F5: Awarded on May 30, 2025 pursuant to the 2023 Plan.
F6: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2026 Filed Aug 18, 2026 20:28 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 9,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000131 · wk-form4_1787084910.xml · derivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,537 Underlying: Common Stock · 9,934 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 30, 2025 pursuant to the 2023 Plan. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6 · derivative.exercise_date: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. F6 · derivative.expiration_date: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:28 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000131 · wk-form4_1787084910.xml · derivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,947 Underlying: Common Stock · 5,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. F4 · derivative.expiration_date: One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:28 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 5,055 | $22.72 | $114,849.60 |
DisclosureSEC source: 0001438133-26-000131 · wk-form4_1787084910.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,260 F1 · kind: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:28 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 9,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000131 · wk-form4_1787084910.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:28 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 3,044 | $22.72 | $69,159.68 |
DisclosureSEC source: 0001438133-26-000131 · wk-form4_1787084910.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,381 F1 · kind: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:28 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000131 · wk-form4_1787084910.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:21 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 191,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000113 · wk-form4_1780431679.xml · derivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,103 Underlying: Common Stock · 191,103 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of the Issuer's common stock or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F2 · derivative.exercise_date: One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter. F2 · derivative.expiration_date: One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 39,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · derivative · entry 10 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,471 Underlying: Common Stock · 39,735 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Awarded on May 30, 2025 pursuant to the 2023 Plan. F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F9 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F9 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · derivative · entry 9 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,929 Underlying: Common Stock · 5,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan, as amended. F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · derivative · entry 8 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 1,336 | $10.90 | $14,562.40 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 7 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,443 F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 18,944 | $12.82 | $242,862.08 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,107 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 39,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 3,044 | $12.82 | $39,024.08 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,316 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 2,785 | $12.82 | $35,703.70 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,378 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · derivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,911 Underlying: Common Stock · 5,983 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan, as amended. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · derivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,472 Underlying: Common Stock · 5,471 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 2,400 | $18.95 | $45,480.00 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,691 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 1,963 | $18.95 | $37,198.85 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,108 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000213 · wk-form4_1763586420.xml · derivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,894 Underlying: Common Stock · 5,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan, as amended. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000213 · wk-form4_1763586420.xml · derivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,943 Underlying: Common Stock · 5,472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 3,038 | $18.61 | $56,537.18 |
DisclosureSEC source: 0001438133-25-000213 · wk-form4_1763586420.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,600 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000213 · wk-form4_1763586420.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 2,779 | $18.61 | $51,717.19 |
DisclosureSEC source: 0001438133-25-000213 · wk-form4_1763586420.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,656 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000213 · wk-form4_1763586420.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 22:14 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-040844 · wk-form4_1755641672.xml · derivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,876 Underlying: Common Stock · 5,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan, as amended. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 22:14 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-040844 · wk-form4_1755641672.xml · derivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,415 Underlying: Common Stock · 5,471 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 22:14 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 3,038 | $10.82 | $32,871.16 |
DisclosureSEC source: 0001628280-25-040844 · wk-form4_1755641672.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,963 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 22:14 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-040844 · wk-form4_1755641672.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 22:14 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 2,779 | $10.82 | $30,068.78 |
DisclosureSEC source: 0001628280-25-040844 · wk-form4_1755641672.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,019 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 22:14 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-040844 · wk-form4_1755641672.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2025 Filed Aug 11, 2025 22:15 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | PurchaseCommon Stock | 10,000 | $10.23 | $102,318.00 |
DisclosureSEC source: 0001438133-25-000165 · wk-form4_1754950540.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,327 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.19 to $10.33 per share. The reported price reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 30, 2025 Filed Jun 5, 2025 21:24 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 119,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000131 · wk-form4_1749158471.xml · derivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,206 Underlying: Common Stock · 119,206 shares Expires not disclosed F1 · security: Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 30, 2025 Filed Jun 5, 2025 21:24 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantPerformance Stock Unit · Derivative | 119,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000131 · wk-form4_1749158471.xml · derivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,204 Underlying: Common Stock · 119,204 shares Expires not disclosed F1 · security: Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F2 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2027 (the Measurement Date). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F2 · derivative.exercise_date: Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2027 (the Measurement Date). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F2 · derivative.expiration_date: Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2027 (the Measurement Date). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 23,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 13 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,858 Underlying: Common Stock · 23,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan. F9 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F12 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F12 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 12 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,886 Underlying: Common Stock · 5,472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F9 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 2,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 11 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan. F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 792 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 10 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 792 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 12,152 | $22.70 | $275,850.40 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 9 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,327 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 23,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 8 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 2,779 | $22.70 | $63,083.30 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 7 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,550 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,472 | $22.70 | $124,214.40 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 1,136 | $22.70 | $25,787.20 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,857 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 2,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 403 | $22.70 | $9,148.10 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,757 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 792 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.